Abstract
Background and aim. Numerous non-invasive markers of liver fibrosis have been described but their clinical implementation is still a matter of controversy. Recent studies indicate that their performance may improve when combined. Two algorithms have been proposed to stage liver fibrosis in hepatitis C, combining either fibroscan and fibrotest (Castera's algorithm, gastroenterology 2005) or fibrotest and AST-to-platelet ratio (APRI) (sequential algorithm for fibrosis evaluation, SAFE biopsy, J Hepatol 2006).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
